ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
67.083,06
0,00%
Brent Oil
83,76
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. NexImmune Inc (NEXI)

  7. NexImmune Inc (NEXI) Notícias

NEXI

NexImmune (NEXI)

NexImmune Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NEXI
DataHoraFonteTítuloCódigoCompanhia
15/05/202417:01Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:NEXINexImmune Inc
09/05/202413:39Business WireApprobation des résultats financiers du groupe au 31 mars 2024, poursuite de la croissance et de l’augmentation de la marge de BAIIA, lancement d’un programme de rachat d’actions de 500 millions €NASDAQ:NEXINexImmune Inc
09/05/202413:39Business WireKonzernabschluss zum 31. März 2024 verabschiedet, kontinuierliches Wachstum und Ausweitung der EBITDA-Marge, Aktienrückkaufprogramm in Höhe von 500 Millionen Euro gestartetNASDAQ:NEXINexImmune Inc
09/05/202403:00Business WireGroup Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, € 500 Million Share Buy-Back Program LaunchedNASDAQ:NEXINexImmune Inc
07/03/202415:20Business WireKonzernergebnis zum 31. Dezember 2023 genehmigt, starke Margenausweitung und Liquiditätsüberschuss von 601 Millionen Euro, Aktienrückkaufprogramm von 500 Millionen EuroNASDAQ:NEXINexImmune Inc
07/03/202414:33Business WireApprobation des résultats financiers du groupe au 31 décembre 2023 ; forte expansion de la marge et génération d'excédents de trésorerie à hauteur de 601 millions d’euros ; programme de rachat d’actions de 500 millions d’eurosNASDAQ:NEXINexImmune Inc
07/03/202403:31Business WireApprovati i risultati finanziari di Gruppo al 31 dicembre 2023, Forte espansione dell’EBITDA margin ed excess cash generation a € 601 milioni, € 500 milioni per acquisto di azioni proprieNASDAQ:NEXINexImmune Inc
07/03/202403:30Business WireGroup Financial Results as of December 31st 2023 Approved, Strong Margin Expansion and Excess Cash Generation at € 601 Million, € 500 Million Share Buy-Back ProgramNASDAQ:NEXINexImmune Inc
06/02/202418:42GlobeNewswire Inc.NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NEXINexImmune Inc
06/02/202418:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NEXINexImmune Inc
05/02/202419:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
05/02/202418:34Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NEXINexImmune Inc
02/02/202416:00GlobeNewswire Inc.NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NEXINexImmune Inc
22/11/202319:40Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:NEXINexImmune Inc
22/11/202319:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NEXINexImmune Inc
21/11/202318:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NEXINexImmune Inc
20/11/202319:19Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NEXINexImmune Inc
20/11/202319:01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:NEXINexImmune Inc
17/11/202318:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NEXINexImmune Inc
09/11/202319:47Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:NEXINexImmune Inc
09/11/202311:35Business WireFinanzergebnisse der Gruppe zum 30. September 2023 bestätigen solide finanzielle Leistung im Rahmen des Plans und kontinuierliche Ausweitung der EBITDA-MargeNASDAQ:NEXINexImmune Inc
09/11/202310:52Business WireLes résultats financiers du groupe au 30 septembre 2023 ont été approuvés, croissance solide conforme au plan, avec une augmentation continue de la marge de BAIIANASDAQ:NEXINexImmune Inc
09/11/202303:30Business WireApprovati I Risultati Finanziari Di Gruppo Al 30 Settembre 2023 Solida Performance in Linea Con I Piani E Continua Crescita Dell’EBITDA MarginNASDAQ:NEXINexImmune Inc
09/11/202303:30Business Wire Group Financial Results as of September 30th 2023 Approved Solid Growth Performance in Line With Plan, With Continued EBITDA Margin ExpansionNASDAQ:NEXINexImmune Inc
24/10/202309:00GlobeNewswire Inc.NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 DiabetesNASDAQ:NEXINexImmune Inc
19/10/202309:00GlobeNewswire Inc.NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual MeetingNASDAQ:NEXINexImmune Inc
18/10/202312:30GlobeNewswire Inc.NexImmune Announces 1-for-25 Reverse Stock SplitNASDAQ:NEXINexImmune Inc
08/09/202320:23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NEXINexImmune Inc
31/08/202317:45GlobeNewswire Inc.NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development StrategyNASDAQ:NEXINexImmune Inc
10/08/202317:01GlobeNewswire Inc.NexImmune Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:NEXINexImmune Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NEXI

Seu Histórico Recente

GATE
DOGNFTETH
The Doge NFT
BIT
S24923
SG ISSUER
COIN
ADCUSD
BIT
UC4AYG
Unicredit Bank
NASDAQ
SPKAR
SPK Acquisition
COIN
POLYXUSD
Polymesh
BOV
ITUBT354
ITUBT354 Ex:34,16
AMEX
EFSH.WS
1847
BOV
VALEL680
VALEL680 Ex:65,33
LSE
AG14
Citi Fun 24
BIT
F19192
Vontobel Financial Produ...
COIN
AC3USD
TG
BHI
Black Hills
USOTC
LBLCF
Loblaw Companies (PK)
COIN
APCBTC
NASDAQ
AGFY
Agrify
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados